EuroPCR 2024 | 2 Year Outcomes of the New Sirolimus Eluting Bioadaptor vs Resolute Onyx Zotarolimus Elulting Stent

Stent related adverse events after the first year see a constant 2-3% annual increase, reaching 20% by year 5 and 50% by year 10. BIOADAPTADOR RCT outcomes at 12 months have shown the safety and efficacy of DynamX Bioadaptor, establishing new reference parameters in arterial viability restoration. The aim of this study was to report<a href="https://solaci.org/en/2024/05/17/europcr-2024-2-year-outcomes-of-the-new-sirolimus-eluting-bioadaptor-vs-resolute-onyx-zotarolimus-elulting-stent/" title="Read more" >...</a>

ACC 2024 | ULTIMATE-DAPT Trial

The international guidelines recommend the use of dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor during 12 months in patients receiving percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), to prevent events such as MI and stent thrombosis.  This was a multicenter, placebo controlled, double blind study to determine whether ticagrelor alone,<a href="https://solaci.org/en/2024/04/10/acc-2024-ultimate-dapt-trial/" title="Read more" >...</a>

AGENT-IDE: Drug Coated Balloons for Instent Restenosis

Drug eluting stents (DES) have improved considerably over the years, reducing the initial indices of instent restenosis (ISR) by roughly 5-10% a year in USA. However, DES failure might lead to neointimal hyperplasia and neoatherosclerosis, which increases the chance of developing chronic and acute coronary syndromes.  Drug coated balloons (DCB), which administer anti-proliferative agents with<a href="https://solaci.org/en/2024/03/21/agent-ide-drug-coated-balloons-for-instent-restenosis/" title="Read more" >...</a>

Se publicaron los resultados del estudio RESPECT con excelentes novedades

Lithotripsy in the Left Main Coronary Artery

A lesion ≥50% in the left main coronary artery (LMCA) is considered severe, according to various scientific societies, regardless of the presence of symptoms or ischemia, due to the extent of myocardium at risk. In such cases, revascularization is indicated. In many patients, lesions in this section of the coronary artery have severe calcification, which<a href="https://solaci.org/en/2024/03/13/lithotripsy-in-the-left-main-coronary-artery/" title="Read more" >...</a>

Función de la mano luego del acceso radial distal, ¿es seguro?

KODRA Registry: Distal Radial Access as First Choice in Coronary Procedures

The first experiences with distal radial access (DRA) have revealed significant benefits compared against the transradial approach (TRA), showing reduced bleeding events and better puncture site occlusion rate. Even the spectrum of diseases treated with DRA has grown, and now includes chronic total occlusion (CTO) though 7Fr inductors, such as Terumo’s Glidesheath Slender. The aim<a href="https://solaci.org/en/2024/02/20/kodra-registry-distal-radial-access-as-first-choice-in-coronary-procedures/" title="Read more" >...</a>

Dieta proinflamatoria y su potencial para desencadenar eventos cardiovasculares

Preparation Before Elective Coronary Angiography: Is Prolonged Fasting the Only Option?

When scheduling a coronary angiography, patients are usually instructed to fast for at least 8 hours (no oral intake after dinner). However, this strategy can lead to negative effects such as discomfort, irritability, dehydration, and even hypoglycemia in some cases. Previous studies have not shown significant differences in gastric complications between patients fasting only 2 hours before<a href="https://solaci.org/en/2024/02/09/preparation-before-elective-coronary-angiography-is-prolonged-fasting-the-only-option/" title="Read more" >...</a>

Events According to Revascularization Modality in the ISCHEMIA Trial

The main studies carried out on patients with chronic coronary syndromes (CCS), such as the MASS II, COURAGE, BARI 2D and FAME-2, failed to show benefits in terms of mortality with the invasive approach.  The ISCHEMIA, a large randomized study including patients with moderate to severe ischemia, with without left main disease and with acceptable<a href="https://solaci.org/en/2024/01/31/events-according-to-revascularization-modality-in-the-ischemia-trial/" title="Read more" >...</a>

Relación entre calidad del vaso distal y resultados en tratamiento percutáneo de las oclusiones totales crónicas

EuroCTO: Safety and Benefit at 3 Years

Chronic total occlusions (CTOs) account for approximately 15-20% of patients with stable coronary artery disease. This field has seen various advances regarding treatment, leading to an improvement in the success rate of procedures. According to registries and randomized studies, the main indication for percutaneous coronary intervention (PCI) of CTO should be based more on clinical<a href="https://solaci.org/en/2023/07/24/eurocto-safety-and-benefit-at-3-years/" title="Read more" >...</a>

Diffuse Coronary Artery Disease: One-Year 48mm XIENCE Skypoint Outcomes

Long 48mm Stent XIENCE Skypoint in the treatment of diffuse CAD Long coronary artery lesions often involve complex decision making since they can be treated either with a long stent or with shorter overlapping stents. Both in registries and meta-analysis, the overlapping technique has been associated to increased target vessel revascularization and increased radioscopy time,<a href="https://solaci.org/en/2023/06/08/diffuse-coronary-artery-disease-one-year-48mm-xience-skypoint-outcomes/" title="Read more" >...</a>

Resultados alentadores de los balones cubiertos de Biolimus para el tratamiento de vasos pequeños

PICCOLETO-II: Drug-Coated Balloons in Small Vessels

Use of drug-coated balloons vs. drug-eluting stents in small caliber vessels. The constant advancements in coronary device technology have significantly reduced complication rates (such as that of restenosis). However, there are gaps where a high number of undesirable events prevail, such as small vessel disease (SVD), for which, in previous studies up, the rate of<a href="https://solaci.org/en/2023/04/28/piccoleto-ii-drug-coated-balloons-in-small-vessels/" title="Read more" >...</a>

chronic stable angina